Therapeutics & Diagnostics companies in Finland
Finland's therapeutics and diagnostics companies come largely out of university research, above all in Helsinki and also in Turku, Tampere and Oulu. They include clinical-stage drug developers in cancer and neurodegenerative disease, blood-analysis and molecular-diagnostics platforms, and tools for drug formulation and research. Most are still pre-revenue, as is typical for drug development.
In market 8
Product is being sold.
-
Helsinki · founded 2021Automated compounding of personalised medicines in pharmacies and hospital pharmacies: Pharma Printer compounding robot + 3D-printable drug inks + quality control (4× faster). Founded 2021; offices…
-
Turku · founded 2015NGS library-prep technologies (Geno1®, Bridge Capture™): ultra-sensitive, PCR-free, >50% cheaper. Oncology — early detection and residual-disease monitoring.
-
Helsinki · founded 2017Tience® — sterile, cell-free injectable derived from adipose tissue that restarts the skin's own regeneration (scars, ageing-related defects, soft-tissue repair). Positioned as a regenerative platform, not a…
-
Helsinki · founded 2022Metabolic-level diagnostics — measurement of NAD coenzymes (kits) for research and health.
-
Helsinki · founded 2015 · 📈 ListedNanoparticle technology for drug formulation (CESS® production + STARMAP® AI) — improves bioavailability and delivery.
-
Helsinki · founded 2002 · 📈 ListedNMR blood analysis + disease-risk prediction (preventive health). Ran the metabolomics profiling for UK Biobank's entire ~500,000-participant cohort — the largest dataset of its kind.
-
Espoo · founded 2025Enzyme-free amplification of single protein molecules (PCR-like) for ultra-sensitive diagnostics / multiomics. VTT spin-off; Lifeline & Cloudberry.
-
Oulu · founded 2008 · Exit / acquiredUltraprecise piezo micromanipulators, automated microscope stages and pressure controllers (uMp/uMs/uMc) for electrophysiology and neuroscience imaging. Founded 2008 to commercialise micropositioning…
Pre-revenue 25
No sales yet.
-
Turku · founded 2025Non-invasive, antibody-free phage-biosensor diagnostics (cancer, infections, neurodegeneration) from accessible samples (saliva, urine) — strong patent portfolio. Series A in preparation; JVs in China (HK…
-
Helsinki · founded 2022Small molecules against high-priority Gram-negative pathogens (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae) with a dual mechanism — neutralising bacterial toxins and disrupting…
-
Kuopio · founded 2010Multi-target cell and gene therapy for chronic wounds and cancer. Lead product AUP-16 is a genetically engineered, non-pathogenic Lactococcus cremoris delivering four therapeutic proteins directly into the…
-
Helsinki · founded 2023Signal-peptide optimisation to boost biopharmaceutical production. Voima portfolio.
-
Oulu · founded 2022Fully synthetic, short-chain antimicrobial peptides engineered to resist enzymatic breakdown, pH, heat and salinity, with broad-spectrum activity including ESKAPE pathogens. First product: a smart…
-
Helsinki · founded 2022Non-invasive predictive cancer screening for dogs (later other pets). BF Deep Tech Accelerator.
-
Espoo · founded 2011Allergy immunotherapy: engineered recombinant allergens for faster, safer desensitisation (birch, peanut, cat). Products in development.
-
Turku · founded 2006 · 📈 ListedClinical-stage immuno-oncology company based in Turku, led by Markku Jalkanen and dual-listed on Nasdaq First North and the London Stock Exchange's AIM market.
-
Espoo · founded 2008 · 📈 ListedClinical-stage neurodegeneration therapy (HER-096, CDNF-based) developed from research by University of Helsinki professors Mart Saarma and Kari Alitalo.
-
Oulu · founded 2026MyoGel™ — a hydrogel extracted from benign human leiomyoma tissue, replacing Matrigel (which comes from mouse sarcoma) in 3D cell culture and drug testing, and stable at room temperature. Developed in…
-
Ylöjärvi · founded 2025Next-generation vaccine platform for pandemic viruses: a proprietary enterovirus platform using virus-like particles (VLP) to trigger a protective immune response, including against viruses traditional vaccine…
-
Helsinki · founded 2023Rapid-acting, non-hallucinogenic neuroplasticity enhancers for major depression and other brain disorders. Lead candidate KTX-0141 targets the TrkB receptor without binding serotonin receptors; first human…
-
Tampere · founded 2024Clinical-grade hyaluronic-acid bioink/hydrogel platform (Glue4Life) for tissue engineering and regenerative medicine — scalable biomaterial production + 3D bioprinting (human stem cells). Univ. of Tampere…
-
Helsinki · founded 2023Patented assay quantifying individual differences in how cells take up and store lipids, read from white blood cells including monocytes — it predicts how well cholesterol-lowering drugs will work in a given…
-
Helsinki · founded 2022
Engineered natural killer cells (CAM NK) for cancer — a patented FasL-enhanced platform improves tumour-killing across a broad target range. Univ. of Helsinki Kumpula campus, preclinical. FIB member + Health…
-
Helsinki · founded 2026Personalised bone-health analysis (blood gene markers + imaging + ML) for early detection of osteoporosis and fractures. Own assays + curated databases. Arctic15 100 Innovations 2026.
-
Helsinki · founded 2023Small-molecule drugs for neurodegenerative diseases. Univ. of Helsinki roots (2023), Innovestor funding.
-
Jyväskylä · founded 2022Bacteriophage technology to replace antibiotics — one of the world's largest phage collections + Phagenomics software. BF Deep Tech Accelerator.
-
Helsinki · founded 2016Precision drug for rare soft-tissue sarcomas (GIST, liposarcoma): SAR001 = reformulated depot anagrelide targeting PDE3A overexpressed in sarcomas. Preclinical.
-
Helsinki · founded 2018Novel high-throughput spatial transcriptomics: a 160,000-picowell chip + colour-coded beads create visual coordinates read by AI from microscope images → single-cell resolution in tissue, in situ. Cancer…
-
Helsinki · founded 2025Patient-specific tumour-on-chip: reproduces the tumour microenvironment and shows in real time how an individual cancer responds to immunotherapies and combinations, so the therapy can be chosen before the…
-
Tampere · founded 2021Regenerative cell therapy for corneal blindness (from iPS cells + biomaterials; off-the-shelf therapy for limbal stem-cell deficiency). Preparing Series A.
-
Helsinki · founded 2013Oncolytic viruses for solid-tumour immunotherapy (turns 'cold' tumours 'hot'; TILT-123, cytokine-armed adenovirus). Clinical stage.
-
Tampere · founded 2001Vaccine technologies and candidates (type 1 diabetes, coeliac, asthma/allergy): flagship is a multivalent enterovirus/Coxsackie B vaccine to prevent T1D — Phase 1 human trial complete. Sole owner of the T1D…
-
Helsinki · founded 2016Oncolytic viruses / cancer immunotherapy (PeptiCRAd platform).
Research projects (pre-company) 1
University and VTT commercialisation projects — no legal entity or funding round yet. Not a complete national list.
-
DDOPAGuardUniversity of Helsinki · Helsinki
Single-molecule dual inhibitor that protects levodopa from gut microbial degradation — aiming for longer-lasting, cheaper Parkinson's disease treatment. University of Helsinki R2B, co-led by professors Mikko…
Other sectors
How this list was made
Every company is checked by hand against the trade register and its own material, and placed in the one sector that best describes its business or technology. Service firms and consultancies are left out. The full rules are on the landscape ↗